Skip to main content

Table 2 Prevalence of HPV by Bethesda classification system

From: Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis

HPV Type Bethesda classification # studies Reference(s) # cases Total sample size % Prevalence (95% CI) from meta-analysis
HR Negative† 9 [31, 35, 39, 48, 49, 51, 52, 54, 57] 1451 15102 40.5% (26.4%-54.6%)
  Benign 2 [51] 42 275 15.7% (9.3%-22.0%)
  ASC-US 5 [31, 39, 48, 51, 53, 54] 136 350 40.5% (26.4%-54.6%)
  LSIL 10 [31, 35, 39, 45, 48, 49, 51, 52, 54, 57] 928 1563 73.6% (55.3%-91.8%)
  HSIL 8 [31, 35, 39, 45, 51, 54, 57, 78] 559 628 89.9% (84.8%-95.1%)
  Cervical Cancer 2 [51, 54] 2 3 *
16 Negative 6 [35, 3941, 48, 52] 473 6017 7.9% (4.9%-11.0%)
  Benign 1 [39] 2 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 7 [35, 3941, 45, 48, 52] 506 1925 28.3% (15.1%-41.5%)
  HSIL 7 [35, 3941, 45, 48, 61] 516 1068 54.0% (45.6%-62.4%)
  Cervical Cancer 3 [38, 43, 61] 81 172 48.8% (34.0%-63.6%)
18 Negative 5 [35, 39, 40, 42, 48] 156 4891 3.6% (1.6%-5.6%)
  Benign 1 [39] 14 250 *
  ASC-US 1 [48] 2 17 *
  LSIL 6 [35, 39, 40, 42, 48, 52] 81 1312 5.8% (3.6%-7.9%)
  HSIL 5 [35, 39, 40, 42, 48] 47 662 7.9% (3.8%-12.0%)
  Cervical Cancer 4 [38, 42, 43, 80] 42 219 17.1% (6.4%-27.9%)
31 Negative 4 [35, 39, 40, 48] 33 4849 2.1% (0.1%-4.1%)
  Benign 1 [39] 2 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 5 [35, 39, 40, 48, 52] 76 1241 7.3% (2.7%-11.8%)
  HSIL 4 [35, 39, 40, 48] 64 432 14.2% (4.0%-24.5%)
  Cervical Cancer 3 [38, 43, 61] 3 172 1.2% (0.0%-2.73%)
33 Negative 4 [35, 39, 40, 48] 38 4849 0.6% (0.0%-1.3%)
  Benign 1 [39] 1 250 *
  ASC-US 1 [48] 2 17 *
  LSIL 4 [35, 39, 40, 48] 35 884 3.6% (1.2%-6.0%)
  HSIL 4 [35, 39, 40, 48] 24 432 5.6% (3.5%-7.8%)
  Cervical Cancer 3 [38, 43, 61] 4 172 2.1% (0.0%-4.2%)
35 Negative 4 [35, 39, 40, 48] 28 4849 0.5% (0.3%-0.8%)
  Benign 1 [39] 1 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 4 [35, 39, 40, 48] 31 884 3.1% (0.3%-6.0%)
  HSIL 4 [35, 39, 40, 48] 8 432 1.8% (0.5%-3.0%)
  Cervical Cancer 3 [38, 43, 61] 0 172 *
39 Negative 3 [39, 40, 48] 11 4770 0.8% (0.0%-2.0%)
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 1 17 *
  LSIL 3 [39, 40, 48] 6 860 0.6% (0.0%-1.5%)
  HSIL 3 [39, 40, 48] 2 374 *
  Cervical Cancer 2 [38, 61] 1 96 *
45 Negative 3 [39, 40, 48] 31 4770 0.6% (0.4%-0.9%)
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 3 [39, 40, 48] 9 860 1.1% (0.4%-1.7%)
  HSIL 3 [39, 40, 48] 6 374 *
  Cervical Cancer 2 [38, 61] 8 96 7.7% (2.4%-13.0%)
51 Negative 3 [39] 7 4470 *
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 1 17 *
  LSIL 3 [39, 40, 48] 2 860 *
  HSIL 3 [39, 40, 48] 3 374 *
  Cervical Cancer 2 [38, 61] 0 96 *
52 Negative 4 [39, 40, 48, 52] 41 5530 1.4% (0.1%-2.7%)
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 1 17 *
  LSIL 4 [39, 40, 48, 52] 50 1217 2.9% (0.8%-5.1%)
  HSIL 3 [39, 40, 48] 9 374 2.4% (0.9%-4.0%)
  Cervical Cancer 2 [38, 61] 3 96 2.6% (0.0%-7.1%)
56 Negative 3 [39, 40, 48] 74 4770 1.4% (0.8%-2.0%)
  Benign 1 [39] 5 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 3 [39, 40, 48] 52 860 5.8% (3.2%-8.3%)
  HSIL 3 [39, 40, 48] 4 374 *
  Cervical Cancer 2 [38, 61] 2 96 1.6% (0.0%-4.1%)
58 Negative 4 [35, 39, 40, 48] 37 4849 1.0% (0.3%-1.6%)
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 4 [35, 39, 40, 48] 22 884 2.3% (1.3%-3.3%)
  HSIL 4 [35, 39, 40, 48] 11 432 2.0% (0.0%-4.3%)
  Cervical Cancer 2 [38, 61] 0 96 *
59 Negative 3 [39, 40, 48] 25 4770 0.5% (0.0%-1.1%)
  Benign 1 [39] 2 250 *
  ASC-US 1 [48] 1 17 *
  LSIL 3 [39, 40, 48] 9 860 0.9% (0.3%-1.6%)
  HSIL 3 [39, 40, 48] 9 374 2.1% (0.7%-3.6%)
  Cervical Cancer 2 [38, 61] 0 96 *
68 Negative 3 [39, 40, 48] 5 4470 *
  Benign 1 [39] 0 250 *
  ASC-US 1 [48] 0 17 *
  LSIL 3 [39, 40, 48] 1 860 *
  HSIL 3 [39, 40, 48] 2 374 *
  Cervical Cancer 2 [38, 61] 1 96 *
  1. Notes: *meta-analysis not feasible due to small numbers, †negative for intraepithelial lesion or malignancy, ‡ includes analyses of all HR types combined (i.e., multiple-infection). Abbreviations: atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL), HSIL high-grade squamous intraepithelial lesions (HSIL).